Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) shares were down 7.5% during mid-day trading on Wednesday . The company traded as low as $4.90 and last traded at $4.90. Approximately 1,174 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 7,832 shares. The stock had previously closed at $5.30.
Pasithea Therapeutics Price Performance
The firm has a 50-day simple moving average of $6.22 and a 200 day simple moving average of $6.91.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($3.70) earnings per share (EPS) for the quarter.
Pasithea Therapeutics Company Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Read More
- Five stocks we like better than Pasithea Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 5 discounted opportunities for dividend growth investors
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- 3 Tickers Leading a Meme Stock Revival
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
